Large gap with delayed quotes
|
Last quote
10/17/2026
-
02:00:00
|
Bid
10/16/2026 -
21:59:59
|
Bid Volume |
Ask
10/16/2026 -
21:59:59
|
Ask Volume |
|---|---|---|---|---|
|
110.16
-3.21
(
-2.83% )
|
110.11
|
400 |
110.16
|
2,300 |
Analysis date: 13.10.2026
Global Evaluation
Neutral
Neutral
The stock is classified in the neutral zone since 04.09.2026.
Quality
Strong
Strong
Three stars since 02.10.2026.
Earnings Rev Trend
Negative
Negative
Compared to seven weeks ago, the analysts have lowered their earnings per share estimates. This negative trend began 02.10.2026 at a price of 116.23.
Evaluation
Undervalued
Undervalued
Based on its growth potential and our own criteria, we believe the share price is currently moderately undervalued.
MT Tech Trend
Positive
Positive
The dividend-adjusted forty day technical trend is positive since 27.03.2026.
4wk Rel Perf
2.50%
2.50%
The four-week dividend-adjusted overperformance versus SP500 is 2.50%.
Risk
Middle
Middle
The stock has been on the moderate-sensitivity level since 18.09.2026.
Bear Market Factor
Middle
Middle
On average, the stock is likely to decline with the index.
Bad News Factor
Low
Low
When the stock's pressure is specific, the market sanction on average is 3.82%.
Mkt Cap in $bn
13.10
13.10
With a market capitalization >$8bn, CORCEPT THERAPEUTICS is considered a large-cap stock.
G/PE Ratio
1.22
1.22
A ratio (Forecasted Growth + Estimated Dividend Yield/ Estimated Price Earnings) higher than 0.9 indicates that the stock's price presents a discount to growth of
LT P/E
10.15
10.15
The estimated PE is for the year 2029.
LT Growth
12.34%
12.34%
The annualized growth estimate is for the current year to 2029.
Avg. Nb analysts
4
4
Over the last seven weeks, an average of 4 analysts provided earnings per share estimates.
Dividend Yield
0.00%
0.00%
The company is not paying a dividend.
Beta
138
138
For 1% of index variation, the stock varies on average by 1.38%.
Correlation
0.19
0.19
Stock movements are totally independent of index variations.
Value at Risk
28.27
28.27
The value at risk is estimated at USD 28.27. The risk is therefore 24.00%. This value is based on the historical volatility for a medium time period (1 month) with a confidence of 95%.
First Analysis Date
15.07.2025
15.07.2025